ISO/TS 20399-2:2018 (E)

Biotechnology — Ancillary materials present during the production of cellular therapeutic products — Part 2: Best practice guidance for ancillary material suppliers

Contents

Foreword

Introduction

1 Scope

2 Normative references

3 Terms and definitions

4 Abbreviated terms

5 General considerations

6 AM characteristics and quality attributes

6.1 AM components, identity and purity
6.1.1 General
6.1.2 Identity and quantity of component(s)
6.1.3 Purity/impurity
6.1.4 Lot-to-lot consistency for AMs containing proprietary components
6.2 AM storage and stability
6.2.1 General
6.2.2 Storage conditions
6.2.3 Stability and expiration dating

7 AM manufacturing and biosafety

7.1 Quality management system
7.2 Manufacturing process
7.3 Container and closure systems
7.4 Animal- and human-derived materials
7.5 Safety to cells and humans

8 AM performance

8.1 General
8.2 Performance assay
8.2.1 General
8.3 Cells used for performance assays
8.4 Performance assay results

9 AM documentation

9.1 General
9.2 Certificate of analysis (CoA)
9.3 Additional certificates
9.3.1 Certificate of origin (CoO)
9.3.2 Certificate of compliance (CoC)
9.3.3 Certificate of irradiation (CoI)
9.4 Other items

Page count: 11